Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 6/1998

Content (14 Articles)

ORIGINAL ARTICLE

Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid

Anna Kruczynski, Francis Colpaert, Jean-Pierre Tarayre, Pierre Mouillard, Jacques Fahy, Bridget T. Hill

ORIGINAL ARTICLE

Phase II trial of combination chemotherapy with cisplatin, carboplatin and etoposide in stage IIIB and IV small-cell lung cancer

Yoichi Nakanishi, Yuji Kawarada, Nobuyuki Hirose, Kiyoshi Ninomiya, Masayuki Miyazaki, Naoki Miyazaki, Yukio Kurita, Hideaki Kanegae, Osamu Ohgushi, Kenichi Ogata, Hiroshi Yamazaki, Satoru Inutsuka, Nobuyuki Hara

ORIGINAL ARTICLE

Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates

Susan M. Blaney, Chris Takimoto, Daryl J. Murry, Nancy Kuttesch, Cynthia McCully, Diane E. Cole, Karen Godwin, Frank M. Balis

ORIGINAL ARTICLE

Clinical and pharmacokinetic studies of high-dose levamisole in combination with 5-fluorouracil in patients with advanced cancer

Joel M. Reid, John S. Kovach, Michael J. O'Connell, Pamela G. Bagniewski, Charles G. Moertel

ORIGINAL ARTICLE

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents

Claire A. Coggins, Gertrude B. Elion, Peter J. Houghton, C. Bradley Hare, O. Michael Colvin, Darell D. Bigner, Henry S. Friedman

ORIGINAL ARTICLE

Effects of polyamine analogues on prostatic adenocarcinoma cells in vitro and in vivo

Gregory P. Zagaja, Maneesh Shrivastav, Laurence J. Marton, Carrie W. Rinker-Schaeffer, M. Eileen Dolan, Matthew F. Fleig

CLINICAL TRIAL REPORT

High-dose-intensity combination chemotherapy for advanced sarcomas: a pilot study

Paolo Pronzato, Pierluigi Losardo, Floriana Pensa, Alessandra Tognoni

SHORT COMMUNICATION

Effect of the multidrug resistance modulator valspodar on serum cortisol levels in rabbits

Tanja Cufer, Ivan Vrhovec, Marija Pfeifer, Janez Skrk, Simona Borstnar, Branimir I. Sikic

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine